Cancer ResearchGLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in Major Study
A large observational study from the University of Pennsylvania found that women taking GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — were about 30% less likely to develop breast cancer. The study reviewed health records from over 111,000 women aged 45–80 with a BMI of 25 or higher who underwent breast imaging between 2022 and 2025. Roughly 14% were GLP-1 users. While the findings are promising, researchers caution this is observational data and cannot prove cause and effect. Clinical trials are now being planned to test whether these drugs can actively prevent breast cancer, particularly in high-risk women.
